Chronic renal disease, even with minor impairment of renal function, has only recently been recognized as a cardiovascular risk factor. Hillege et al 1 confirmed and extended this knowledge substantially in their article. In their study, renal impairment was predictive of adverse outcome in patients with a broad spectrum of heart failure. Although the epidemiological relationship seems to be clear beyond any doubt, theories on the pathophysiological mechanism(s) underpinning such a link have not taken into full account all the available knowledge on this issue. One particular mechanism, the increased concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), would fit well with the findings in this study. In patients with renal diseases, ADMA is increased even when the glomerular filtration rate is still within the normal range. 2 Epidemiological studies showed that ADMA is a strong predictor of cardiovascular mortality in patients with coronary artery disease and patients with moderate renal failure, as well as in dialysis patients. 3, 4 Acute infusion of ADMA in healthy volunteers reduces cardiac output, increases systemic vascular resistance, and triggers a well-defined decrease in renal perfusion. 5 Most importantly, ADMA is strongly associated with renal hemodynamic changes in patients with early heart failure, therefore should be regarded as a potential candidate mediating the cardio-renal link.
